SecBot SecBot
SECBOTREPLAY Home › Report › CORT

CORT · Corcept Therapeutics reported full-year 2025 revenue of $761.4 million,…

CORCEPT THERAPEUTICS INC · 8-K filed Feb 24, 2026 at 16:10 ET

At the news

BULLISHIMPACT 7/10

8-K filed Feb 24, 2026 at 16:10 ET

Corcept Therapeutics reported full-year 2025 revenue of $761.4 million, a 12.8% increase from 2024, driven by strong demand in its Cushing's syndrome business despite supply constraints. However, net income declined 29.4% to $99.7 million due to higher operating expenses. The company issued bullish 2026 revenue guidance of $900–$1,000 million, representing 18–32% growth, and highlighted key upcoming catalysts including a July 2026 PDUFA date for relacorilant in ovarian cancer and data readouts from multiple late-stage trials.

  • 2025 revenue: $761.4 million (up 12.8% YoY from $675.0 million)
  • 2025 net income: $99.7 million (down 29.4% YoY from $141.2 million)
  • 2025 diluted EPS: $0.82 (down 33.3% YoY from $1.23)
  • Full-year 2026 revenue guidance: $900–$1,000 million (18–32% growth)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access